
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/FFD865. CME/MOC/NCPD credit will be available until April 20, 2026.
The Innovation Intersection in B-Cell Cancers: Navigating Choices With Modern Targeted Strategies, Cellular Therapy, and HCT
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Lilly.
Disclosure information is available at the beginning of the video presentation.
4.4
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/FFD865. CME/MOC/NCPD credit will be available until April 20, 2026.
The Innovation Intersection in B-Cell Cancers: Navigating Choices With Modern Targeted Strategies, Cellular Therapy, and HCT
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Lilly.
Disclosure information is available at the beginning of the video presentation.
763 Listeners
810 Listeners
127 Listeners
6 Listeners
17 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
28 Listeners
3 Listeners
3 Listeners
4 Listeners
4 Listeners
4 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
320 Listeners
2 Listeners
110 Listeners
12 Listeners
2 Listeners
55 Listeners
91 Listeners
3 Listeners
44 Listeners
21 Listeners
48 Listeners
55 Listeners
165 Listeners
36 Listeners